Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Yuki Ikematsu"'
Autor:
Yuki Ikematsu, Miiru Izumi, Koichi Takayama, Hiroyuki Kumazoe, Kentaro Wakamatsu, Masayuki Kawasaki
Publikováno v:
Thoracic Cancer, Vol 13, Iss 18, Pp 2616-2623 (2022)
Abstract Background It has long been thought that small‐cell lung cancer (SCLC) is a central type of tumor that is located in the proximal bronchi and the mediastinum. However, several studies reported that SCLC exhibited several types of spread pa
Externí odkaz:
https://doaj.org/article/953345b0e64949f8b48912c912b736c7
Autor:
Nobuhisa Ando, Kentaro Tanaka, Kohei Otsubo, Gouji Toyokawa, Yuki Ikematsu, Maako Ide, Yasuto Yoneshima, Eiji Iwama, Hiroyuki Inoue, Kayo Ijichi, Tetsuzo Tagawa, Yoichi Nakanishi, Isamu Okamoto
Publikováno v:
Thoracic Cancer, Vol 11, Iss 10, Pp 2830-2839 (2020)
Background Mps one binder kinase activator 1 (MOB1) is a core component of the Hippo signaling pathway and has been implicated as a tumor suppressor. Here, we evaluated the possible relationship of MOB1 expression in non‐small cell lung cancer (NSC
Externí odkaz:
https://doaj.org/article/060ff2c22887419e905a3d5dd7168eed
Autor:
Yuki Ikematsu, Miiru Izumi, Tsuyoshi Ueno, Yuki Moriuchi, Mizuko Ose, Naotaka Noda, Makiko Hara, Junji Otsuka, Kentaro Wakamatsu, Masayuki Kawasaki
Publikováno v:
Respirology Case Reports, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Edwardsiella tarda is an anaerobic, gram‐negative rod bacterium associated with freshwater and marine life. Human E. tarda infections are rare, and most infections in humans cause gastroenteritis. Extraintestinal infections of E. tarda suc
Externí odkaz:
https://doaj.org/article/af527124bc4f476cbbe5fe22c2a6041a
Autor:
Yuki Ikematsu, Miiru Izumi, Katsuyuki Katahira, Tsuyoshi Ueno, Yuki Moriuchi, Mizuko Ose, Naotaka Noda, Makiko Hara, Junji Otsuka, Kentaro Wakamatsu, Masayuki Kawasaki
Publikováno v:
Respiratory Medicine Case Reports, Vol 37, Iss , Pp 101642- (2022)
Werner syndrome (WS) is a rare progressive disorder that is characterized by premature aging of all organs. Malignancy is a frequent complication of WS, however, lung cancer patients with WS are much rare. In patients with WS, the treatment for malig
Externí odkaz:
https://doaj.org/article/176fae80c8d14b8483a8a636f4eebffb
Autor:
Younosuke Sato, Isamu Okamoto, Hiroki Kameyama, Shinji Kudoh, Haruki Saito, Mune Sanada, Noritaka Kudo, Joeji Wakimoto, Kosuke Fujino, Yuki Ikematsu, Kentaro Tanaka, Ayako Nishikawa, Ryo Sakaguchi, Takaaki Ito
Publikováno v:
Diagnostics, Vol 10, Iss 11, p 949 (2020)
Small-cell lung cancer (SCLC) is an aggressive malignant cancer that is classified into four subtypes based on the expression of the following key transcription and co-transcription factors: ASCL1, NEUROD1, YAP1, and POU2F3. The protein expression le
Externí odkaz:
https://doaj.org/article/02eaa6cdf3964096ba4e11fbe6f362b8
Autor:
Koji Okamura, Hiroyuki Inoue, Kentaro Tanaka, Yuki Ikematsu, Rie Furukawa, Keiichi Ota, Yasuto Yoneshima, Eiji Iwama, Isamu Okamoto
Publikováno v:
Cancer Science. 114:1095-1107
Malignant pleural mesothelioma (MPM) is an aggressive solid cancer with a poor prognosis, whereas coxsackievirus A11 (CVA11) is a potential oncolytic virus for cancer treatment. We here investigated the oncolytic activity of CVA11 with human MPM cell
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer
Autor:
Kentaro Tanaka, Kenji Chamoto, Sho Saeki, Ryusuke Hatae, Yuki Ikematsu, Kazuko Sakai, Nobuhisa Ando, Kazuhiro Sonomura, Shinsuke Kojima, Masanori Taketsuna, Young Hak Kim, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Tomoko Hirano, Fumihiko Matsuda, Toyohiro Hirai, Kazuto Nishio, Takuro Sakagami, Masanori Fukushima, Yoichi Nakanishi, Tasuku Honjo, Isamu Okamoto
Publikováno v:
Science translational medicine. 14(675)
Despite the success of cancer immunotherapies such as programmed cell death–1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination therapies with PD-1/PD-L1 inhibitors are needed to overcome this issue. Be
Autor:
Gouji Toyokawa, Kohei Otsubo, Yasuto Yoneshima, Nobuhisa Ando, Yoichi Nakanishi, Kentaro Tanaka, Yuki Ikematsu, Kayo Ijichi, Eiji Iwama, Maako Ide, Isamu Okamoto, Tetsuzo Tagawa, Hiroyuki Inoue
Publikováno v:
Thoracic Cancer, Vol 11, Iss 10, Pp 2830-2839 (2020)
Thoracic Cancer
Thoracic Cancer
Background Mps one binder kinase activator 1 (MOB1) is a core component of the Hippo signaling pathway and has been implicated as a tumor suppressor. Here, we evaluated the possible relationship of MOB1 expression in non‐small cell lung cancer (NSC
Autor:
Yuki Ikematsu, Miiru Izumi, Tsuyoshi Ueno, Yuki Moriuchi, Mizuko Ose, Naotaka Noda, Makiko Hara, Junji Otsuka, Kentaro Wakamatsu, Masayuki Kawasaki
Publikováno v:
Respirology Case Reports. 10
Autor:
Hitoshi Kusaba, Yasuto Yoneshima, Yoichi Nakanishi, Hiroyuki Inoue, Kunihiro Suzuki, Yuki Ikematsu, Kentaro Tanaka, Eiji Iwama, Isamu Okamoto, Kohei Otsubo, Masako Arimura-Omori, Eiji Harada, Takuji Yamauchi, Naoki Hamada, Koichiro Matsumoto, Toyoshi Yanagihara
Publikováno v:
International Immunology. 32:547-557
Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes and are becoming a standard treatment for many cancer types. However, these drugs also induce immune-related adverse events, among which interstitial lung disease (ILD) is potentiall